BRCA1 and melanoma: For instance, CX-5461 is utilized for the treatment of BRCA1/2 deficient tumors through topoisomerase II inhibition [97,98], and melanoma cell lines have been treated with G4 ligand RHPS4 that targets the MYC gene [99] among others.